-
-
LTB4
chemotactic factor for neutrophile and T cells
-
L-8
chemotactic factor for neutrophils and monocytes
-
IFN-g
cytokine that augments inflammatory response
-
IL-1B and IL-6
amplify the inflammatory process
-
transforming growth factor(TGF-B)
induces fibrosis
-
Pulmonary symptoms (9)
- cough
- hemopysis
- chest pain
- dysphagia
- sputum
- dyspnea
- hoarsness
- pleural effusion
- pneumonitis
-
extrapulmonary systems (4)
- bone, arm, shoulder pain
- liver dysfunction
- neurologis
- SVC obstruction
-
paraneoplastic syndromes(6)
- weight loss
- cushings
- SIADHS
- anemia
- hypercalceima
- eaton-lambert
-
AE with bevacizumab(3)
- hypertension
- proteinuria
- bleeding
-
antimetabolites (lung cancer)
- Gemcitabine
- pemetrexed
- not cell cycle specific (dose)
-
Microtubule targeting druge
- vinorelbine
- vinblastine
- paclitaxel
- docetaxel
- M phase
-
-
Heavy Metal
- cisplatin
- carboplatin
- S phase (maybe)
-
Growth factor agents
- erlotinib
- cetuximab
- bevacizumab
- not cycle specific (dose)
-
AE with gemcitabine
- DL - myelosuppression
- anemia, leucopenia, neutropenia
-
AE with pemetrexed
- mucositis
- myelosuppression
- thrombocytopenia
- rash in 1/2 pts
-
AE with docetaxel
- DL neutropenia
- fluid retention
- alopecia
-
AE withPaclitaxel
- sig neutropenia
- alopecia
- hypersensiivity rxns
-
AE with etoposide
- leucopenia
- alopecia
- NV
- (worse in pts with decreased serum albumin)
-
AE with cisplatin
nephrotoxicity
-
AE with carboplatin
Myelosuppression
-
antimetabolites (cancer)
- fluorouracal (5-FU)
- Antifolates
- -MXT
-
alkylating agents (cancer)
- cyclephosphamide
- ifosamide
|
|
